Resilience Biosciences is a clinical-stage biopharmaceutical company developing herbal and small-molecule therapeutics for opioid withdrawal, pain, and cognitive deficits.
About
Resilience
Biosciences
We leverage translational neuroscience, clinical research, herbal medicine, and modern chemistry to create innovative, science-driven solutions to critical unmet needs.
Inspired by nature, driven by science and innovation.
About
Our Company
Mission
RBI is committed to improving patient outcomes and helping address global public health challenges related to opioid dependence, withdrawal-associated pain, and cognitive impairment.
Company
Turning clinical and neurobiological insights into high-impact therapeutics. Learn More
Team
Expertise across drug development, neuroscience, psychiatry, and chemistry. Learn More
Research Pipeline
RBI is pursuing 3 synergistic research pipelines. Learn More
Publications
Papers in published in peer-reviewed journals. Learn More
About
Research Pipelines
RBI-01
12-plant, non-opioid herbal formulation. Learn More
RBI-02
Novel T-type calcium channel antagonists. Learn More
RBI-03
Novel, nature-inspired dopamine modulator. Learn More
Research Pipeline
RBI is pursuing 3 synergistic research pipelines. Learn More
Publications
Papers in published in peer-reviewed journals. Learn More
About
Research
Pipeline
RBI-01
12-plant, non-opioid herbal formulation. Learn More
RBI-02
Novel T-type calcium channel antagonists. Learn More
RBI-03
Novel, nature-inspired dopamine modulator. Learn More